Abstract: A method of handling PUSCH data retransmission collision, in a user terminal of TDD, wherein, the user terminal uses a first UL/DL configuration mode in a first radio frame, the method comprises the following steps: receiving a reconfiguration message from a base station, the reconfiguration message is used to indicate the user terminal to use a second UL/DL configuration mode in a second radio frame; judging whether PHICH for a first PUSCH data transmission is located in the first radio frame; if yes, judging whether the second radio frame includes a collision subframe, wherein, the downlink subframe occupied by the PHICH is also used to bear uplink retransmission resource allocation; when including, determining a retransmission uplink subframe used to retransmit PUSCH data by using a remapping scheme, when the second radio frame includes the collision subframe; and retransmitting the PUSCH data in the retransmission uplink subframe.

Abstract: A pharmaceutical composition is provided which includes sorafenib and GW5074. This combination therapy inhibits cancer cell growth via c-Raf-PP2A-DAPK signaling transduction pathway in either an in vitro or pre-clinical animal model for orthotopic spontaneous kidney cancer which simulates clinical symptoms. Formation of the bond between c-Raf and GW5074 leads to conformational change which consequently increases the affinity between sorafenib and c-Raf. Binding with the specific drug target facilitates serine 308 dephosphorylation of DAPK by PP2A and induces necrosis in cancer cells. Serine 308 of DAPK protein may also be used as a biomarker for drug screening. A novel pharmaceutical composition is provided which includes sorafenib and GW5074, a protein complex target consisting of c-Raf and DAPK for drug designing, as well as biomarkers including c-Raf protein, DAPK protein and phosphorylation status of DAPK for drug screening.

Abstract: Embodiments of the present invention provide an interference cancellation method for an enhanced physical downlink control channel E-PDCCH, comprising steps of: (1) allocating different orthogonal covering code OCC sequences to different cells and/or different users; and (2) combining a plurality of control channel elements CCEs constituting one PDCCH with a cell-specific OCC sequence and/or a user-specific OCC sequence respectively, so as to enable a user equipment to cancel interference on the PDCCH.

Abstract: In order to reduce the feedback overhead of channel state information in Coordinated Multipoint (CoMP) transmission, the present invention provides a method of determining a channel state in the CoMP transmission, wherein the serving base station receives first channel state information with the serving base station and second channel state information with each of coordinated base stations, fed back by a user equipment; informing each coordinated base stations of the corresponding second channel state information; precoding a first reference signal according to the first channel state information, and sending the precoded first reference signal to the user equipment on the communication resource commonly used with the coordinated base station, wherein the first reference signal is superimposed with precoded second reference signals respectively sent by each of coordinated base stations; receiving third channel state information fed back by the user equipment according to the superimposed reference signal, an

Abstract: Novel GP-83 protein (human epididymis-associated disintegrin and metalloprotease 7 protein) and nucleic acid molecules are disclosed. The invention provides purified GP-83 protein, fusion protein, antigenic peptides, and anti-GP-83 antibodies. The invention also provides isolated GP-83 nucleic acid molecule, recombinant vectors containing the GP-83 nucleic acid molecule, host cells containing the recombinant vector, and non-human transgenic animals in which the GP-83 nucleic acid molecule has been introduced or interrupted.

Abstract: Novel GP-83 protein (human epididymis-associated disintegrin and metalloprotease 7 protein) and nucleic acid molecules are disclosed. The invention provides purified GP-83 protein, fusion protein, antigenic peptides, and anti-GP-83 antibodies. The invention also provides isolated GP-83 nucleic acid molecule, recombinant vectors containing the GP-83 nucleic acid molecule, host cells containing the recombinant vector, and non-human transgenic animals in which the GP-83 nucleic acid molecule has been introduced or interrupted.

Abstract: An improved cytoplasmic male sterile line and improved production of hybrid soybean plants which utilizes the control of a single nuclear restorer gene to impact sterility. A cytoplasmic male sterile soybean plant is provided, wherein fertility is restored through the introduction of a dominant allele at a nuclear restorer gene locus. Maintenance of the cytoplasmic male sterile soybean line is achieved through cross pollination with a male fertile isoline wherein the isoline has a fertile cytoplasm gene and recessive alleles at a nuclear restorer gene locus. The cytoplasmic male sterile line can be used as a female in the production of hybrid soybean plants when cross-pollinated with a male sterile restorer line having dominant restorer allele at the nuclear restorer gene loci. The resulting seeds are harvested from the female plant and can be planted to grow male fertile F1 plants.